- Trial Name
- SYNAPSE-SMA
- Age:
- 18 to 75 years old.
- Aim:
- To evaluate the efficacy, safety, tolerability and pharmacokinetics of NMD670 in the treatment of ambulatory adults with SMA type 3.
- Status:
- Recruiting
- Locations:
- Belgium, Canada, Denmark, Germany, Italy, Netherlands, Spain, USA
- Identifier:
- NCT05794139
Clinical Trials
Overview
NMD-670
Developed by NMD Pharma, NMD-670 is a small molecule that targets skeletal muscle, with the potential to increase responsiveness to weak nerve signals and support more consistent muscle function.
It has also been studied in other neuromuscular diseases, such as myasthenia gravis, and is currently being evaluated in a clinical trial to assess its safety and efficacy in ambulatory adults with SMA.
Method of Action
NMD-670 is a small molecule that increases muscle contractions by inhibiting CIC-1, a chloride channel that causes muscles to relax. In doing so, the molecule is thought to increase muscle strength and function.
Trial of NMD-670
Press releases
- 14th December 2022: NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3 - NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3 — NMD Pharma